Illumina, Inc. (ILMN): Price and Financial Metrics
Illumina, Inc. (ILMN)
Today's Latest Price: $309.69 USD
Updated Oct 29 9:09am
Add ILMN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ILMN Stock Summary
- With a market capitalization of $45,214,740,000, Illumina Inc has a greater market value than 95.78% of US stocks.
- The price/operating cash flow metric for Illumina Inc is higher than 90.2% of stocks in our set with a positive cash flow.
- With a price/sales ratio of 13.49, Illumina Inc has a higher such ratio than 89.43% of stocks in our set.
- Stocks that are quantitatively similar to ILMN, based on their financial statements, market capitalization, and price volatility, are NTES, ADI, VMW, ATVI, and SPOT.
- Visit ILMN's SEC page to see the company's official filings. To visit the company's web site, go to www.illumina.com.
ILMN Stock Price Chart Interactive Chart >
ILMN Price/Volume Stats
| Current price | $309.69 | 52-week high | $404.20 |
| Prev. close | $309.69 | 52-week low | $196.78 |
| Day low | $309.69 | Volume | 1,197 |
| Day high | $309.69 | Avg. volume | 1,277,464 |
| 50-day MA | $326.88 | Dividend yield | N/A |
| 200-day MA | $324.30 | Market Cap | 45.21B |
Illumina, Inc. (ILMN) Company Bio
Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.
ILMN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $309.69 | $147.37 | -52% |
Below please find a table outlining a discounted cash flow forecast for ILMN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Illumina Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Illumina Inc ended up being:
- The company's debt burden, as measured by earnings divided by interest payments, is 21.05; that's higher than 86.41% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 12.64% of the free cash flow producing stocks we're observing.
- ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 45.87% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -53% |
| 1% | -53% |
| 2% | -52% |
| 3% | -52% |
| 4% | -51% |
| 5% | -51% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ILMN, try CPIX, JNJ, LMAT, ZTS, and HAPP.
Loading social stream, please wait...